摘要
目的：评价阿立哌唑治疗精神分裂症的疗效及安全性。方法：采取随机对照研究方法。120例精神分裂症患者随机分为阿立哌唑组60例，剂量10-30mg／d；利培酮组60例，剂量2—6mg／d，疗程6周。治疗前后用阳性症状和阴性症状量表（PANSS）、副反应量表（TESS）、血生化指标和心电图的改变评定疗效和安全性。结果：①阿立哌唑组自治疗第2周末，利培酮组自治疗第4周末，PANSS阳性、阴性症状分、精神病理症状分和总分均明显下降（P〈0．05或P〈O．01）。治疗第6周末，阿立哌唑组PANSS阳性症状分（9．8±5．7）分，阴性症状分（24．2±8．7）分，精神病理症状分（16．7±5．8）分，总分（55．8±7．9）分，与基线分[分别为（16．8±7．2）分，（41．2±9．4）分，（26．4±9．6）分，（81．7±16．4）分]的差异均有统计学意义（P〈0．01），且疗效优于利培酮组。②治疗第6周末，阿立哌唑组治愈22例（36％），显著进步19例（32％），进步10例（17％），症状无显著变化7例（12％），恶化2例（3％）；治愈率为36％，显效率为68％，有效率为85％，高于利培酮组（66％）。③6周的观察期中，未发现阿立哌唑导致的体质量明显增加及心电图明显改变。结论：阿立哌唑对精神分裂症有良好疗效，起效较迅速，安全性较好。
Objective： To evaluate the efficacy and safety of aripiprazole in treatment of patients with acute exacerbation of schizophrenia.Methods： A randomized, controlled clinical trial was conducted. All subjects （n = 120） receive 6 weeks treatment with either atepiprezole （n = 60） or risperidone （n = 60）, with the dosage of 10 - 30mg/d and 2 - 6mg/d respectively. Efficacy and adverse reactions were assessee with Positive And Negative Symptoms Scale （PANSS） ,and Treatment Emergent Symptoms Scale （TESS） and the changes of biochemical index and electrocardiogram at baseline before and after treatments. Results： In aripiprazole group, the positive, the negative, psychopathological snbscale and total score of PANSS were significantly decreased （ P 〈 0.05 or P 〈 0.01 ） after 2 - week treatment, hut the decrease occurred after 4 - week treatment in risperidone group. After 6 - week aripiprazole treatment, the PANSS scores （positive： 9.8 ± 5.7, negative： 24.2± 8.7, total： 55.8 ± 7.9） were significantly reduced in comparison with the baseline（positive： 16.8 ± 7.2, negative：41.2 ± 9.4, total： 81.7 ± 16.4） （ P 〈 0.01 ）, with better efficacy than risperidone. In this 6 - week study, weight gain and abnormalities in electrocardiogram were not found in aripiprazole treatment group.Conclusion： Aripiprazole is effective and safe in treatment of the patients with acute schizophrenia.
出处
《中国民康医学》
2009年第8期799-800,900,共3页
Medical Journal of Chinese People’s Health
